Mycobacterium avium complex (MAC)

Mycobacterium avium complex (MAC) is a group of related acid-fast bacilli, primarily including Mycobacterium avium and Mycobacterium intracellulare, which are environmental organisms commonly found in water and soil [StatPearls - Mycobacterium Avium Complex]. As opportunistic pathogens, they represent the most frequent cause of nontuberculous mycobacterial (NTM) infections, typically manifesting as chronic pulmonary disease in individuals with pre-existing lung damage or as disseminated infections in immunocompromised patients, particularly those with advanced HIV/AIDS [CDC - NTM; NIH - StatPearls]. The complex is characterized by a thick, lipid-rich cell wall that facilitates intracellular survival within host macrophages and provides significant intrinsic resistance to many standard antibiotics [PMID: 32663116]. From a pharmacological perspective, MAC is the object of multi-drug therapeutic regimens that target essential bacterial machinery, such as protein synthesis, RNA transcription, and cell wall assembly [ATS/IDSA Guidelines 2020]. Successful management is often hindered by the necessity for long-term treatment (often 12 months beyond culture conversion), significant drug toxicities, and the risk of developing acquired resistance to cornerstone drugs like macrolides.

Other names

Mycobacterium avium-intracellulare complexMAICMACNontuberculous mycobacteria (NTM) - MAC group

Antibiotics targeting Mycobacterium avium complex act by inhibiting various essential bacterial processes: macrolides (clarithromycin, azithromycin) and aminoglycosides (amikacin) inhibit protein synthesis at the 50S and 30S ribosomal subunits respectively; ethambutol inhibits arabinosyltransferase to disrupt cell wall synthesis; rifamycins (rifampin, rifabutin) inhibit DNA-dependent RNA polymerase; and bedaquiline inhibits mycobacterial ATP synthase [StatPearls - Mycobacterium Avium Complex; PMID: 32663116].